Who is sponsoring NCT05702645?

NCT05702645 is sponsored by Children's Oncology Group.

What drugs are being tested in NCT05702645?

Interventions in NCT05702645: Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment, Questionnaire Administration, Survey Administration.

What condition does NCT05702645 study?

NCT05702645 studies B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome.

Is NCT05702645 still recruiting?

NCT05702645 is currently recruiting now. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT05702645

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Recruiting now Last updated 24 February 2026

What this trial tests

trial testing Biospecimen Collection in B Acute Lymphoblastic Leukemia Associated With Down Syndrome in 330 participants. Currently enrolling.

Timeline

30 November 2023

Primary endpoint
30 June 2029

30 June 2029

Quick facts

Lead sponsor	Children's Oncology Group
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	330
Start date	30 November 2023
Primary completion	30 June 2029
Estimated completion	30 June 2029
Sites	70 locations across Canada, United States

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Clinical Evaluation — full drug profile →
Neurocognitive Assessment
Questionnaire Administration
Survey Administration

Conditions studied

B Acute Lymphoblastic Leukemia Associated With Down Syndrome — all drugs for B Acute Lymphoblastic Leukemia Associated With Down Syndrome →
Down Syndrome — all drugs for Down Syndrome →
Myeloid Leukemia Associated With Down Syndrome — all drugs for Myeloid Leukemia Associated With Down Syndrome →

Sponsor

Children's Oncology Group — full company profile →

Who can join

Adults 6 to 39, any sex, with B Acute Lymphoblastic Leukemia Associated With Down Syndrome or Down Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A multicenter observational cohort study in survivors of Down Syndrome-associated acute leukemia (ALTE22C1): a report from the Children's Oncology Group.
Gramatges MM, Sanclemente LN, Hall L, Taylor OA, et al · · 2025 · PMID 41116168 · DOI 10.1186/s12885-025-14898-z

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other Children's Oncology Group trials

Trials by the same sponsor.

NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05702645 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05702645.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing